- Home
- TCBIO vs TNGX Comparison
TCBIO vs TNGX Comparison
Compare TCBIO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBIO
- TNGX
- Stock Information
- Founded
- TCBIO N/A
- TNGX 2014
- Country
- TCBIO United States
- TNGX United States
- Employees
- TCBIO 1987
- TNGX N/A
- Industry
- TCBIO Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TCBIO Finance
- TNGX Health Care
- Exchange
- TCBIO Nasdaq
- TNGX Nasdaq
- Market Cap
- TCBIO N/A
- TNGX 735.0M
- IPO Year
- TCBIO N/A
- TNGX N/A
- Fundamental
- Price
- TCBIO $21.32
- TNGX $6.64
- Analyst Decision
- TCBIO
- TNGX Strong Buy
- Analyst Count
- TCBIO 0
- TNGX 8
- Target Price
- TCBIO N/A
- TNGX $15.14
- AVG Volume (30 Days)
- TCBIO N/A
- TNGX 885.7K
- Earning Date
- TCBIO N/A
- TNGX 11-06-2024
- Dividend Yield
- TCBIO N/A
- TNGX N/A
- EPS Growth
- TCBIO N/A
- TNGX N/A
- EPS
- TCBIO N/A
- TNGX N/A
- Revenue
- TCBIO N/A
- TNGX $42,509,000.00
- Revenue This Year
- TCBIO N/A
- TNGX $18.15
- Revenue Next Year
- TCBIO N/A
- TNGX N/A
- P/E Ratio
- TCBIO N/A
- TNGX N/A
- Revenue Growth
- TCBIO N/A
- TNGX 26.16
- 52 Week Low
- TCBIO N/A
- TNGX $6.33
- 52 Week High
- TCBIO N/A
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- TCBIO 53.15
- TNGX 37.15
- Support Level
- TCBIO $21.15
- TNGX $6.83
- Resistance Level
- TCBIO $21.49
- TNGX $7.47
- Average True Range (ATR)
- TCBIO 0.34
- TNGX 0.37
- MACD
- TCBIO 0.00
- TNGX 0.11
- Stochastic Oscillator
- TCBIO 73.68
- TNGX 27.31
About TCBIO Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Texas Capital Bancshares Inc is a secured lender, with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. The company's national lines of business provide specialized lending products to businesses throughout the United States. The bank operates in Texas' main metropolitan areas, like Austin, Dallas, Fort Worth, Houston, and San Antonio.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.